Colorimetric, Ultra-structural and Elemental Comparison of Dental Enamel Defects
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jan 7, 2021
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying specific types of enamel defects in teeth, which can occur due to conditions like Amelogenesis Imperfecta, dental fluorosis, and Molar Incisor Hypomineralization. The researchers are using a special tool called the Zfx SpectroShade® to measure the color of teeth and help identify these enamel issues early, even before the teeth come in. The goal is to see if this tool can be a simple and non-invasive way to diagnose these problems, which can help with better dental care.
To participate in the trial, individuals must be between 8 and 55 years old and have one of the three enamel conditions mentioned. It's important that participants do not have any other dental problems or are undergoing treatments that could affect their teeth. Those who join the study can expect to have their teeth examined using the color measurement tool, and the researchers will also look at the structure and characteristics of the enamel from extracted teeth or samples. This research could lead to better understanding and treatment options for people with enamel defects in the future.
Gender
ALL
Eligibility criteria
- For patients :
- Inclusion Criteria :
- • 1. Age between 8 and 55 years old
- • 2. Carrier of one of the following 3 quantitative pre-eruptive enamel anomalies : AIH, dental fluorosis or MIH
- • 3. Information and collection of the non-opposition of the adult patient or of the representative(s) of parental authority present for the minors.
- Criteria for non-inclusion :
- • 1. Pregnant or breastfeeding woman
- • 2. Under guardianship or curators
- • 3. Opposition of the minor patient
- • 4. Presenting pre-eruptive anomalies only on the molars (the spectrophotometer can only take pictures of the anterior dental sector (incisors and canines)).
- • 5. Other types of hypomineralization (post-eruptive, of traumatic or infectious origin, idiopathic).
- • 6. Having undergone radiotherapy or chemotherapy inducing dental and periodontal damage.
- • 7. Having systemic abnormalities (unbalanced diseases), haemochromatosis, porphyria
- • 8. Under medication likely to disturb the coloring of the teeth
- For witnesses :
- Inclusion Criteria :
- • 1. Age between 8 and 55 years old
- • 2. Information and collection of the non-opposition of the adult witness or of the representative(s) of parental authority present for the minors.
- • 3. Free of any anomaly of tooth structure, exogenous dyschromia and carious lesions.
- Criteria for non-inclusion :
- • 1. Pregnant or breastfeeding woman
- • 2. Under guardianship or curators
- • 3. Opposition of the minor witness
- • 4. Carrier of a quantitative pre-eruptive enamel anomaly
- • 5. Polycarpus (preventing the diagnosis of amyl hypomineralization)
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials